During Thursday’s trade, Shares of Avago Technologies Limited (NASDAQ:AVGO), gained 9.99% to $145.36.
Avago Technologies Limited stated financial results for the fourth fiscal quarter and fiscal year ended November 1, 2015, and offered guidance for the first quarter of its fiscal year 2016.
Basis of Presentation
Avagos financial results comprise results from LSI Corporations (LSI) ongoing operations starting the third fiscal quarter of 2014, from PLX Technology Inc. starting in the fourth fiscal quarter of 2014, and from Emulex Corporation (Emulex) starting the third fiscal quarter of 2015, in each case from the date of their acquisition. The financial results from businesses that have been classified as suspended operations in the Companys financial statements are not comprised in the results presented below, unless otherwise stated.
Avago Technologies Limited designs, develops, and supplies semiconductor devices with a focus on analog III-V based products. The company operates through four segments: Wireless Communications, Wired Infrastructure, Enterprise Storage, and Industrial & Other segments.
Shares of Dollar General Corporation (NYSE:DG), inclined 3.70% to $67.75, during its current trading session.
Dollar General Corporation declared the promotion of John W. Garratt to executive vice president and chief financial officer (CFO), effective December 2, 2015. Garratt has served as Dollar General’s interim CFO since June 2015 and formerly served as its senior vice president of finance and strategy since joining the Company in October 2014.
Additionally, Anita C. Elliott, senior vice president and controller at Dollar General since 2005, has been designated chief accounting officer (CAO). Elliott will report to Garratt in his role as CFO, effective December 2, 2015.
Dollar General Corporation, a discount retailer, provides various merchandise products in the southern, southwestern, midwestern, and eastern United States.
Finally, Dyax Corp. (NASDAQ:DYAX), surged 11.90%, and is now trading at $37.33, after the biotech said the U.S. Federal Trade Commission had ended the antitrust waiting period for the company’s acquisition by Shire PLC, Dyax shares rallied 13% to $37.83 on heavy volume. The potential $6.5 billion deal was declared in early November, and shares of Dyax have gained more than 40% since speculation on the deal started in October. Shire is offering $37.30 a share for Dyax, together with another $4 a share with the approval of Dyax’s DX-2930 hereditary angioedema treatment.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.